SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Charts for Quick CASH $$$

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Galirayo who wrote (6157)2/10/1998 2:08:00 AM
From: scaram(o)uche  Read Replies (1) of 9262
 
[ bio stos ]

Lots of biotechs tonight, including ARIA, CLGY, MEDX, REGN, BTGC and ENMD. ENMD focuses on inhibiting the growth of new blood vessels that cancers need for growth. CLGY is a favorite of Mark Lampert.....
Message 3330337

I don't follow them, but I like Lampert's taste. MEDX is big in cancer, and is counting on lots of licensing revenue from their "GenPharm" project, human antibodies that originate from mice. Story is still out. BTGC was on Friday's sto, and (disclaimer) I bought some today. I also own REGN and ARIA, and, coincidentally, the Lehman Brothers site that I mentioned earlier today also has an update on ARIA.......

lehman.com

So, obviously, I like BTGC, REGN and ARIA best of those that I noticed on tonight's lists. ARIA is, IMO, the best science bang for the buck followed by REGN. Early-stage biotechs are always risky, however.

I'll check news in the morning.

Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext